[1]曹运兰,胡龙江,宋耀明.核苷酸结合寡聚化结构域样受体蛋白3炎性体在2型糖尿病并发冠心病过程中的作用[J].第三军医大学学报,2017,39(08):801-806.
 Cao Yunlan,Hu Longjiang,Song Yaoming.Role of nucleotide binding oligomerization domain-like receptor protein 3 inflammasome in occurrence of coronary heart disease in patients with type 2 diabetes mellitus[J].J Third Mil Med Univ,2017,39(08):801-806.
点击复制

核苷酸结合寡聚化结构域样受体蛋白3炎性体在2型糖尿病并发冠心病过程中的作用(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
39卷
期数:
2017年第08期
页码:
801-806
栏目:
临床医学
出版日期:
2017-04-30

文章信息/Info

Title:
Role of nucleotide binding oligomerization domain-like receptor protein 3 inflammasome in occurrence of coronary heart disease in patients with type 2 diabetes mellitus
作者:
曹运兰胡龙江宋耀明
第三军医大学新桥医院心血管内科,全军心血管病研究所;重庆市涪陵中心医院心血管内科
Author(s):
Cao Yunlan Hu Longjiang Song Yaoming

Department of Cardiology, Institute of Cardiovascular Diseases, Xinqiao Hospital, Third Military Medical University, Chongqing, 400038; Department of of Cardiovascular Diseases, Chongqing Fuling Central Hospital, Chongqing, 408000, China

关键词:
核苷酸结合寡聚化结构域样受体蛋白3炎性体冠心病2型糖尿病IL-1&beta
Keywords:
nucleotide binding oligomerization domain-like receptor protein 3 inflammasome coronary heart disease type 2 diabetes mellitus interleukin-1&beta
分类号:
R341;R587.1;R541.4
文献标志码:
A
摘要:

目的      探究核苷酸结合寡聚化结构域样受体蛋白3(nucleotide binding oligomerization domainlike receptor protein 3,NLRP3)炎性体在2型糖尿病并发冠心病过程中的作用。方法      选取第三军医大学新桥医院心血管内科的住院患者共130例,分为单纯冠心病组(n=40)、单纯2型糖尿病组(n=20)、2型糖尿病并发冠心病组(n=40)及正常对照组(n=30)。分离外周血单个核细胞及血浆。采用RT-qPCR、Western blot分别检测各组外周血单个核细胞中NLRP3、凋亡相关斑点样蛋白(apoptosis-associated speck-like protein,ASC)、半胱天冬氨酸蛋白酶-1(caspase-1) mRNA及蛋白表达情况,ELISA法检测各组血浆中IL-1β含量。结果      单纯冠心病组、单纯2型糖尿病组及2型糖尿病并发冠心病组外周血单个核细胞中NLRP3、ASC、Caspase-1 mRNA及蛋白表达水平均较正常对照组显著增高(P<005),其中,2型糖尿病并发冠心病组ASC、Caspase-1 mRNA在外周血单个核细胞中的表达显著高于单纯冠心病组及单纯2型糖尿病组(P<0.05),而2型糖尿病并发冠心病组NLRP3蛋白在外周血单个核细胞中的表达显著高于单纯冠心病组及单纯2型糖尿病组(P<0.05)。同时,测得单纯冠心病组、单纯2型糖尿病组及2型糖尿病并发冠心病组血浆中IL-1β含量分别为(24.05±1.00)、(22.86±1.66)、(26.85±1.45)ng/L,较正常对照组(12.53±2.79)ng/L均显著升高(P<0.05),其中,2型糖尿病并发冠心病组血浆中IL-1β含量显著高于单纯冠心病组及单纯2型糖尿病组(P<0.05)。结论     NLRP3炎性体的异常激活可促进2型糖尿病并发冠心病病理过程的发生、发展,其可能成为防治2型糖尿病并发冠心病的新靶点。

Abstract:

Objective      To investigate the role of inflammasome of nucleotide binding oligomerization domainlike receptor protein 3 (NLRP3) in the occurrence of coronary heart disease (CHD) in patients with type 2 diabetes mellitus (T2DM). Methods     One hundred and thirty patients hospitalized in the Department of Cardiology, Xinqiao Hospital between March and August 2016 were enrolled in this study, including 40 with CHD, 20 with T2DM group, and 40 with T2DM complicated by CHD, with 30 individuals without T2DM or CHD serving as the control group. Peripheral blood monocytes (HPBMCs) and plasma were collected from the subjects to detect the transcription and protein levels of NLRP3, apoptosis-associated speck-like protein (ASC) and caspase-1 using real-time qPCR and Western blotting; the plasma level of IL-1β was detected with enzyme-linked immunosorbent assay (ELISA). Results     Both the mRNA and protein levels of NLRP3, ASC and caspase-1 in the HPBMCs were significantly increased in patients with CHD, T2DM and T2DM complicated by CHD groups as compared with the control group (P<0.05). HPBMCs from diabetic patients with CHD patients showed significantly higher ASC and caspase-1 mRNA levels and NLRP3 protein level than those from CHD or T2DM patients (P<0.05). The mean plasma levels of IL-1β were 24.05±1.00, 22.86±1.66, and 26.85±1.45 ng/L in CHD, T2DM and T2DM complicated by CHD groups, respectively, all significantly higher than the level in the control group (12.53±2.79 ng/L, P<0.05). Conclusion     The aberrant activation of NLRP3 inflammasome promotes the occurrence of CHD in patients with T2DM and may serve as a new target for prevention and treatment of the CHD in diabetic patients. 

参考文献/References:

[1]Grant R W,Dixit V D. Mechanisms of disease: inflammasome activation and the development of type 2 diabetes[J]. Front Immunol, 2013. 4: 50. DOI:10.3389/fimmu.2013.00050.
[2]Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response[J]. Nature, 2006, 442(7098): 39-44. DOI:10.1038/nature04946.
[3]Binder C J, Chang M K, Shaw P X, et al. Innate and acquired immunity in atherogenesis[J]. Nat Med, 2002, 8(11): 1218-1226. DOI:10.1038/nm1102-1218.
[4]Hansson G K. Inflammation, atherosclerosis, and coronary artery disease[J]. N Engl J Med, 2005, 352(16): 1685-1695. DOI:10.1056/NEJMra043430.
[5]Wen H, Ting J P, O'Neill L A. A role for the NLRP3 inflammasome in metabolic diseases--did Warburg miss inflammation[J]. Nat Immunol, 2012, 13(4): 352-357. DOI:10.1038/ni.2228.
[6]Duewell P, Kono H, Rayner K J, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals[J]. Nature, 2010, 464(7293): 1357-1361. DOI:10.1038/nature08938.
[7]Sun C, Fan S, Wang X, et al. Purple sweet potato color inhibits endothelial premature senescence by blocking the NLRP3 inflammasome[J]. J Nutr Biochem, 2015, 26(10): 1029-1040. DOI:10.1016/j.jnutbio.2015.04.012.
[8]Lee H M, Kim J J, Kim H J, et al. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes[J]. Diabetes, 2013, 62(1): 194-204. DOI:10.2337/db12-0420.
[9]Hayden J M, Reaven P D. Cardiovascular disease in diabetes mellitus type 2: a potential role for novel cardiovascular risk factors[J]. Curr Opin Lipidol, 2000, 11(5): 519-528. DOI:10.1097/00041433-200010000-00010.
[10]Pant S, Deshmukh A, Gurumurthy G S, et al. Inflammation and atherosclerosis—revisited[J]. J Cardiovasc Pharmacol Ther, 2014, 19(2): 170-178. DOI:10.1177/107424841 3504994.
[11]Lu X, Kakkar V. Inflammasome and atherogenesis[J]. Curr Pharm Des, 2014, 20(1): 108-124.
[12]He Y, Zeng M Y, Yang D, et al. NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux[J]. Nature, 2016, 530(7590): 354-357. DOI:10.1038/nature16959.
[13]Satoh M, Tabuchi T, Itoh T, et al. NLRP3 inflammasome activation in coronary artery disease: results from prospective and randomized study of treatment with atorvastatin or rosuvastatin[J]. Clin Sci, 2014, 126(3): 233-241. DOI:10. 1042/CS20130043.
[14]Dowling J K, O’Neill L A. Biochemical regulation of the inflammasome[J]. Crit Rev Biochem Mol Biol, 2012, 47(5): 424-443. DOI:10.3109/10409238.2012.694844.
[15]Haneklaus M, O’Neill L A, Coll R C. Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation: recent developments[J]. Curr Opin Immunol, 2013, 25(1): 40-45. DOI:10.1016/j.coi.2012.12.004.
[16]Bauernfeind F G, Horvath G, Stutz A, et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression[J]. J Immunol, 2009, 183(2): 787-791. DOI:10.4049/ jimmunol.0901363.
[17]Sergin I, Bhattacharya S, Emanuel R, et al. Inclusion bodies enriched for p62 and polyubiquitinated proteins in macrophages protect against atherosclerosis[J]. Sci Signal, 2016, 9(409): ra2. DOI:10.1126/scisignal.aad5614.

相似文献/References:

[1]党万太,谢文光,赵明才,等.痛风性关节炎患者NLRP3炎性体基因转录剪接体mRNA表达与临床检测指标的相关分析[J].第三军医大学学报,2014,36(16):1713.
 Dang Wantai,Xie Wenguang,Zhao Mingcai,et al.Correlation analysis of expression of NLRP3 gene transcript variant mRNA and clinical examination indexes in patients with gouty arthritis[J].J Third Mil Med Univ,2014,36(08):1713.

更新日期/Last Update: 2017-04-24